Get started

Medical

HTBX UpdateI see a cup and handle forecast called out here, which is a possibility with the way the current COVID market is moving. HTBX does have a few bright spots in early faces of trials, one of which for tumor destruction: "PTX-35 is a novel, first-in-class agonist antibody targeting TNFRSF25, also known as death receptor 3 (DR3), a receptor that is preferentially expressed by antigen-experienced T cells." Another of which, a phase 1 COVID trial: "Jeff Wolf, CEO of Heat, commented, "We remain on track to complete design and development of our COVID-19 vaccine in July, and expect that our gp96/nCoV-2 expressing cell line will be available for clinical-grade manufacturing with our partner, Waisman Biomanufacturing, in early August. Given our progress to date, we remain encouraged by the potential of our unique vaccine to provide broad cellular T-cell and humoral protection against COVID-19, as well as possible future mutations or other coronaviruses."" Each of these snippets made available via Yahoo. Three options: 1) Sharp correction and continue to grow to higher highs 2) A bit of a prolonged correction, but still progress expected from the companies overall trends 3) Lower lows and a bust scenario Trading stocks of this value is a very scary market, please do not take as financial advice and merely as informational.
HLong
by CRYPTOG00N2M00N
ATHX ScenariosPurely for my own use as I've been following this (as well as a few other stocks since COVID surged this market sector) for a couple months now. I see 3 options ahead of us after the immediate rejection today near 3.30 mark. 1) A quick correction before another rise after another bounce off the support 2) A two week correction before a bounce off support to bigger and better levels 3) A breakdown in the market and a dip to new lows. Personally, I feel option 1 holds as most likely just based on the sharpness of the rejection this morning. Don't use as trading advice as this is merely for monitoring.
ALong
by CRYPTOG00N2M00N
Bullish Charts - $15 TargetGenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular panels based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California. Good earnings report. Daily chart looks amazing. This stock looks like its ready to pop! Long DISCLAIMER The Content herein is for informational purposes only, you should not construe any such information or other material as legal, tax, investment, financial, or other advice.
GLong
by HotCharts
BIOTRON - Primed to MOVE!Watching BIOTRON closely. 2 Scenarios: 1. Break of internal trend within the symmetrical triangle will see us return to the .065-.080 region (AREA OF INTEREST). -We've had 2 bounces on the .382 Fib region creating a double top @ .115 Equilibrium -Break of internal uptrend trendline. -Currently broken the center band of bollinger bands. -We've also had a death cross on MACD and is starting to spread. -Waiting on break of support at .088 2. If POSITIVE results are announced shortly for any of BIOTRONS Projects/Programs (Anti Viral Drug Program, HIV Program, HBV Program) We should see a break out of Symmetrical Triangle. -Break of downtrend possible. -Retest of .011 Equilibrium VERY possible. -New Market Structure will form with Higher LOW & Higher HIGH. -Volume will be brought back into the market. -My next target would be major resistance at .014 A very interesting company with real world prospects. I have been following them since the earlier in the year, with Phase 2 HIV-1 Clinical Trials being successful, HBV Pre-Clinical Trials and work on Anti Viral Drug Development with a keen interest on Covid-19. These Ideas are NOT 'Financial Advice'!. Scenarios are based off a mixture of TA and Fundamentals current at the time. All IMO GLTAH. Happy Hunting!!!
ASX:BIT
by Trader_Johnni
2
Golden Goose IPO "PPD" This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one as well to play. Pivot points and resistance are $26.86 / $28 / $29.37 on the 4HR time frame. The Linear reg. channel is bullish on all time frames up to the 3 min. when it becomes semi neutral. Listed at 100% buy right now on Robinhood NASDAQ:PPD Inc. provides drug development services to the biopharmaceutical industry, focuses on helping customers bring their new medicines to patients around the world. The firm also provides clinical development and laboratory services to pharmaceutical, biotechnology, medical device and government organizations and other industry participants. Its clinical development services include all phases of development (Phase I-IV), peri- and post-approval and site and patient access services; laboratory services offers advanced testing services, including bioanalytical, biomarker, vaccine, good manufacturing practice and central laboratory services. The company was founded by Fred Eshelma in 1985 and is headquartered in Wilmington, NC.
PLong
by The_OnlyRule
MTNB - Bullish Weekly - Trade the Zones - Play the TicksI actually trade this for 15-20% gains on deep supply zones. Last time I got in was .51 so not bad if you understand where to buy in. I like the swings in this stock and has some volume. Bullish weekly at least to start off next week. Might fail right away with the resistance and the highs. Just need a solid open above .73. Still not banking on that. Just wanted to share a decent penny stock that if you know where to buy in then you can get some decent returns over and over. At least for now. "Reasons Why Long-term Faith on Matinas BioPharma Holdings, Inc. (MTNB) Could Pay Off Investors" investchronicle.com
AMEX:MTNB
by DigitalData
Liberty Health , my ideal small play and hope i am hoping small profitable players in the Mari-Jane field become profitable enough to survive and the space become just another commodity that the big companies do not buy it out and price gauge us its high 29.85 reverse stock splits 1 for 4 , AUG 31 2015 1 for 5 , JUN o3 2016 1 for 3 , JUL 26 so 60 shares became 1 29,85 / 60 = = 0.4975 the high price divided by splits = cost of share price now 0.50 [ 50 cents i will wait till it goes above the channel which looks fairly priced and then when it goes above this channel i will watch for a bad reversal and exit ! if not , let the HI times begin
L
by G13Man
BPTH - Good News in Dec = Enormous ProfitsBPTH, the ticker to the company Bio Path Holdings is currently trending down. This ticker has been a poor performer for the entire year with small time periods where day traders may make an easy 20-60 percent. Bio Path may seem like a decent day trading target where it follows the downward trending line and tends to bounce up a few days after coming into contact with it. If this continues, one can easily make short term gains and find value in this, but it will make much more sense to wait. Bio Path will be releasing news on its number one drug, Prexigebersen for Acute Myeloid Leukemia (AML). This drug with good data has the potential of making Bio Path a multi billion dollar company. As you can see last year, Bio Path jumped from a startling ~$1 per share to ~$70 per share with one good news release. It is not easy to find these opportunities very often, that's why timing is the key. Bio Medical companies tend to slowly decrease in value or, "bleed" waiting for positive news from the company. This is due to the companies being unprofitable and often seek financing deals creating stock dilution. The good news is what makes the stock relatively value because of the opportunity for day traders to capitalize on large percentage gains with a simple news release, but at the same time, you could also lose a large amount if it were negative. Bio Path will release news on Prexigebersen this December and if you don't know enough about it, I recommend you do a little research on your own. Any investment in this company is indeed speculation. Investing with small positions is the proper strategy with bio-med. Cheers, AC
NASDAQ:BPTHLong
by RayleWoodInvestments
NUVA BUYBUY signal at 65.73$. Timeframe - 1 week. Nuvasive, Inc. is a medical device company. The Company focuses on developing minimally-disruptive surgical products and procedurally-integrated solutions for the spine surgery. Its product portfolio focuses on applications for spine fusion surgery, including biologics used to aid in the spinal fusion process. If you want to see more history of this strategy, I able to show you if you request me. It's one of two signal algo for NUVA. ATTENTION this strategy may has downtrend about 10-15%, so you can split your buy order, that you have not big downtrend. __________________________________________________________________________ You can use the signals independently or like indicator of trends together with other indicators in your trading strategy. Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies. You use these signals inside your strategies at your own risk. The chart shows the last trades on the product + the last signal. I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile. Therefore, subscribe and watch for that profile. The signals rare but useful.
NLong
by price_and_time
$VIVE Classic "Cursed After Reversed" Or Can It ReVIVE Itself?VIVE seems like it can't get out of its own way. Great gap up in the morning but yet again, another red close. Even after reversing, shares are back at penny stock levels. So is it doomed to repeat history or can it find a new bottom? I don't know if anyone really knows for sure just yet. "Viveve’s stock price had a terrible September, dropping more than 57%. However, its start to October is looked promising at the start. The healthcare penny stock gapped up over 25% during premarket hours on October 1st. In addition, the penny stock has already tripled its average trading volume. But as you see, VIVE stock has pulled back considerably from those premarket highs."* *Quote Source: 5 Money Making Penny Stocks To Watch This Week Most Recent News: Viveve Raises $6.76 million Through Completion of At-The-Market Equity Financing ENGLEWOOD, CO / ACCESSWIRE / October 1, 2019 / Viveve Medical, Inc. (VIVE), a medical technology company focused on women's intimate health, today announced the completion of its at-the-market (ATM) offering of $6.76 million of shares of its common stock with Ladenburg Thalmann & Co. Inc. as the sales agent. The company sold 1,004,171 shares at a weighted average price of $6.73 per share (adjusting for a reverse stock split of Viveve common stock effected September 18, 2019) resulting in net proceeds of approximately $6.56 million to the company after deduction of sales commissions. As of September 30, 2019, the company had 1,469,589 shares outstanding. About VIVE Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. News Source: finance.yahoo.com
V
by PennyStocks101
1
ALKS BUY 03.09.2019BUY signal at 20.98 $ Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. If you want to see more history of this strategy, I will able to show you if you request me. ATTENTION this strategy may has downtrend about 20%, so you can split your buy order, that you have not big downtrend. __________________________________________________________________________ You can use the signals independently or like indicator of trends together with other indicators in your trading strategy. Know that the success of your strategy that based on those signals depends from your money management and the additional conditions that you make in these strategies. You use these signals inside your strategies at your own risk. The chart shows the last trades on the product + the last signal. I have several strategies for different products, and I want to show you proof of it works on history, and you will be able to see it, when returns to that profile. Therefore, subscribe and watch for that profile. The signals rare but useful.
NASDAQ:ALKSLong
by price_and_time
QUOTIENT LTD - NASDAQ: $QTNT Works On Its BaseFor the better part of 2019, the shares of QUOTIENT LTD - NASDAQ: QTNT have found themselves range-bound trading within the $8 - $11 zone, while seemingly continuing to build and work on its long drawn base as is evidenced in the Daily chart above. While further work is in order, QTNT remains in decent technical shape as the stock presently finds itself trading above all of its important moving averages 20/50/200 DMA's, which constitutes a healthy technical posture. Additionally, when extending out to both the Weekly and Monthly time-frames, one can also observe that QTNT remains in fine shape as well. Therefore, we have a favorable technical picture across multiple time-frames, which bodes well. Thus, while further work is required, both investors/traders may want to continue to monitor the action closely in the days/weeks ahead for further clues/evidence that things may be about to pick-up. In particular, should QTNT be capable of going topside of the $9.75 level, we may just witness a rapid re-test of the $11 level and perhaps a move into the $12 - $14 zone down the road.
Q
by InsiderFinancial
CRIS Trend Holding - More Upside To Come About: Curis, Inc. is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company's drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes. CA-170 is an oral small molecule drug candidate that is designed to selectively target programmed death ligand-1 (PDL1) and V-domain Ig suppressor of T-cell activation (VISTA) immune checkpoint proteins, both of which independently function as negative regulators of immune activation. CA-4948 is an oral small molecule drug candidate that is designed to inhibit the Interleukin-1 receptor-associated kinase 4 (IRAK4) kinase, which is a transducer of toll-like receptor or certain interleukin receptor signaling pathways. SHORT INTEREST 453.34K 06/28/19 P/E Ratio (with extraordinary items) -2.40 Further Information: Each of the Q3 2019 Inducement Grants has an exercise price per share equal to the closing price of the Company's common stock on July 1, 2019. Each stock option has a 10 year term and vests over four years, with 25% of the original number of shares underlying the award vesting on the first anniversary of the employee's date of hire and an additional 6.25% of the original number of shares underlying the award vesting on each successive three-month period thereafter, subject to the employee's continued service with the Company through the respective vesting dates. Each stock option was granted as an inducement equity award outside of the Company's Third Amended and Restated 2010 Stock Incentive Plan and was made as an inducement material to the employee's acceptance of employment with the Company.
NASDAQ:CRISLong
by DEXWireNews